Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesGlobeNewsWire • 05/13/25
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPTBusiness Wire • 04/29/25
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 03/28/25
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and OptionsGlobeNewsWire • 03/13/25
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun PharmaPRNewsWire • 03/10/25
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 03/10/25
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire • 03/10/25
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)GlobeNewsWire • 12/13/24
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 11/12/24
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024GlobeNewsWire • 09/16/24
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market SuccessSeeking Alpha • 08/27/24
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 08/12/24
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 07/25/24
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionGlobeNewsWire • 06/24/24
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 06/06/24
Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Fox Factory Holding Corp. (NASDAQ: FOXF), Snowflake Inc. (NYSE: SNOW), and Nextdoor Holdings, Inc. (NYSE: KIND)Accesswire • 06/05/24